Mark J. Alles

Mark J. Alles is a declared insider at 4 companies (board member); the most frequent names are Celgene Corp /DE/, Biomarin Pharmaceutical Inc and Turning Point Therapeutics, Inc. Over a trading history stretching from 29 January 2016 to 16 September 2023, the count stands at 19 filings.

On the market, this insider has only ever bought: 2 purchases, €452k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 5 share grants and 11 option exercises.

The record was last updated on 19 September 2023 with an option exercise in Syros Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,446 days ago, on 2 November 2022. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.